Hoy J, Kamarulzaman A, De Graaff B; Australasian Society for HIV Medicine. Conference.
Annu Conf Australas Soc HIV Med. 1996 Nov 14-17; 8: 135 (poster no. 170).
OBJECTIVE: To describe the occurrence of fixed drug reaction in 2 patients treated with PEG-IL-2. DESCRIPTION: Patient SDS was treated with continuous infusion (CIV) IL-2 over 12 months. In the maintenance protocol he was treated with PEG-IL-2. Following treatment with PEG-IL-2 he developed delineated lesions (erythematous, pruritic) on both forearms. The lesions resolved without sequelae. The lesions recurred when next treated with PEG-IL-2 (left forearm, back and legs). A punch biopsy was attended. Lesions gradually faded over 1 week. Rash recurred approximately 1 week later. Resolved after 48 hours but left with pigmented sear to left forearm. Clinically (via Dermatology review), it was suggested that the rash represented a fixed drug reaction but there was uncertainty re. the causative factor. Punch biopsy histopathology revealed interface dermatitis with possible epidermal necrosis. Patient GJV was treated with 6 cycles of CIV IL-2 over 12 months. Under the maintenance protocol GJV also opted to be treated with PEG-IL-2. His first treatment cycle with PEG-IL-2 was uneventful. With the second and third cycles the patient developed multiple lesions (delineated, erythematous, mildly raised, one lesion with central tenderness, pruritic). Lesions resolved with sequalae of pigmented scar at one lesion site. This rash was consistent with a clinical diagnosis of fixed drug reaction. CONCLUSION: Generalised erythema and pruritis are common side effects of treatment with IL-2. Both patients had experienced these cutaneous effects of CIV-IL-2 treatment. The relationship between change in treatment arm (ie from CIV IL-2 to PEG-IL-2) and fixed drug reaction is uncertain and the potential role of the PEG component in the aetiology of the fixed drug reaction is considered.
Publication Types:
Keywords:
- Humans
- Interleukin-2
- Polyethylene Glycols
- Viral Vaccines
- chiron
- interleukin-2, polyethylene glycol-modified
Other ID:
UI: 102222006
From Meeting Abstracts